1995;56(23-24):2097-102.
An efficient new cannabinoid antiemetic in pediatric oncology.
Abstract
Delta-8-tetrahydrocannabinol (delta-8-THC), a cannabinoid with lower psychotropic potency than the main Cannabis constituent, delta-9-tetrahydrocannabinol (delta-9-THC), was administered (18 mg/m2 in edible oil, p.o.) to eight children, aged 3-13 years with various hematologic cancers, treated with different antineoplastic drugs for up to 8 months. The total number of treatments with delta-8-THC so far is 480. The THC treatment started two hours before each antineoplastic treatment and was continued every 6 hrs for 24 hours. Vomiting was completely prevented. The side effects observed were negligible.
PMID: 7776837 [PubMed – indexed for MEDLINE]
PMID: 7776837 [PubMed – indexed for MEDLINE]
MeSH Terms, Substances
MeSH Terms
- Adolescent
- Antiemetics/therapeutic use*
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Burkitt Lymphoma/drug therapy*
- Child
- Child, Preschool
- Dronabinol/analogs & derivatives*
- Dronabinol/therapeutic use
- Female
- Hodgkin Disease/drug therapy*
- Humans
- Infant
- Male
- Nausea/chemically induced
- Nausea/drug therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
- Wilms Tumor/drug therapy*